STAAR Surgical’s (STAA) “Equal Weight” Rating Reaffirmed at Stephens

Stephens reiterated their equal weight rating on shares of STAAR Surgical (NASDAQ:STAA) in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a $17.00 price target on the medical instruments supplier’s stock.

A number of other equities analysts also recently commented on the company. William Blair downgraded STAAR Surgical from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 12th. Mizuho cut STAAR Surgical from an “outperform” rating to a “neutral” rating and reduced their price target for the stock from $45.00 to $17.00 in a research note on Wednesday, February 12th. Canaccord Genuity Group reduced their price target on STAAR Surgical from $28.00 to $17.00 and set a “hold” rating on the stock in a research note on Thursday, February 13th. Jefferies Financial Group cut STAAR Surgical from a “buy” rating to a “hold” rating in a research note on Wednesday, February 12th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of STAAR Surgical in a research note on Thursday, February 27th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, STAAR Surgical presently has an average rating of “Hold” and an average target price of $25.29.

STAAR Surgical Stock Down 1.8 %

Shares of STAAR Surgical stock opened at $17.92 on Tuesday. The company has a market cap of $883.90 million, a PE ratio of -43.71 and a beta of 0.66. The business has a 50 day moving average of $19.97 and a 200 day moving average of $25.81. STAAR Surgical has a 52 week low of $13.50 and a 52 week high of $52.68.

Insider Transactions at STAAR Surgical

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. purchased 108,720 shares of the stock in a transaction dated Thursday, March 20th. The shares were purchased at an average cost of $17.96 per share, with a total value of $1,952,611.20. Following the completion of the acquisition, the insider now directly owns 12,182,995 shares in the company, valued at $218,806,590.20. This trade represents a 0.90 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last three months, insiders have purchased 1,036,187 shares of company stock valued at $17,239,548. Insiders own 1.00% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Broadwood Capital Inc. lifted its holdings in STAAR Surgical by 0.7% in the fourth quarter. Broadwood Capital Inc. now owns 10,848,631 shares of the medical instruments supplier’s stock valued at $263,513,000 after acquiring an additional 80,200 shares during the period. Vanguard Group Inc. lifted its holdings in STAAR Surgical by 5.8% in the fourth quarter. Vanguard Group Inc. now owns 5,855,570 shares of the medical instruments supplier’s stock valued at $142,232,000 after acquiring an additional 319,441 shares during the period. State Street Corp lifted its holdings in STAAR Surgical by 0.5% in the third quarter. State Street Corp now owns 1,940,567 shares of the medical instruments supplier’s stock valued at $72,092,000 after acquiring an additional 10,430 shares during the period. Resona Asset Management Co. Ltd. bought a new position in STAAR Surgical in the fourth quarter valued at about $36,411,000. Finally, Geode Capital Management LLC raised its stake in shares of STAAR Surgical by 2.7% in the third quarter. Geode Capital Management LLC now owns 1,174,499 shares of the medical instruments supplier’s stock worth $43,641,000 after buying an additional 31,212 shares during the period. Institutional investors own 96.70% of the company’s stock.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.